Clinical Trials Logo

Filter by:
NCT ID: NCT06253182 Recruiting - Breast Cancer Clinical Trials

Psychosexual Educational Partners Program (PEPP)

PEPP
Start date: April 2, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two Psychosexual Educational programs for women who have completed treatment for breast or gynecological cancer and their partners in preparation for a well-powered phase III study. The investigators plan to enroll 30 dyads in a 2-arm pilot randomized controlled trial (RCT). The primary aim will be to assess the preliminary efficacy of the Psychosexual Educational Partners Program (PEPP) on sexual communication.

NCT ID: NCT06253130 Recruiting - Clinical trials for Advanced Solid Tumor

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Start date: December 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.

NCT ID: NCT06253104 Recruiting - Heart Failure Clinical Trials

Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure

Start date: February 19, 2024
Phase:
Study type: Observational

This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in HF patients before and after advanced therapies using US imaging. Therefore this observational study will provide further insight into the 1) changes in lean body mass during critical illness and 2) the feasibility of using bedside US to assess lean body mass in the inpatient setting.

NCT ID: NCT06252948 Recruiting - Clinical trials for Plasma Cell Disorders

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Microbiome
Start date: December 29, 2021
Phase:
Study type: Observational

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

NCT ID: NCT06252922 Recruiting - Diet, Healthy Clinical Trials

Diet-Induced Changes in GEnetic Material

DIG 'EM
Start date: November 11, 2023
Phase:
Study type: Observational

This is a pilot study in 10 men to test the hypothesis that perturbations in substrate flux and the circulating metabolic and pro-inflammatory milieus during a high-fat diet paradigm will modulate DNA methylation of genes in sperm associated with obesity and cardiometabolic dysfunction.

NCT ID: NCT06252883 Not yet recruiting - Stress Clinical Trials

Impact of Serial Bedside Video Calls on Stress Level in Parents of Infants Admitted to NICU

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this randomized prospective interventional study is to determine if serial bedside video calls w/audio feature to NICU parents in addition to the routine phone and/or bedside updates can reduce parental stress level. The main question it aims to answer is if the impact of audio-visual calls to nicu parents can improve parent-infant relationship in the form of reduced parental anxiety/stress level. Participants will be parents of infants admitted to NICU for more than seven (7) days. Parents in Group A will receive serial video call communication, 2-3 days a week in addition to the daily phone and/or bedside updates. Parents in Group B will receive daily phone and/or bedside updates per our NICU routine. Parents will complete a series of questionnaires (PSS-NICU, STAI Y-1 & 2 and MSPSS) at 3 designated periods during an 8-week time frame. Researchers will compare Group A (intervention group) and Group B (control group) to see if there is any difference in the stress levels in relation to the intervention (serial video calls) at the end of the study time frame.

NCT ID: NCT06252753 Recruiting - Clinical trials for Hepatobiliary Cancers

Observational Study Protocol: LIVER-R

LIVER-R
Start date: December 20, 2023
Phase:
Study type: Observational

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).

NCT ID: NCT06252727 Not yet recruiting - Soft Tissue Sarcoma Clinical Trials

Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This will be a prospective pilot study that will evaluate 20 patients who were diagnosed with FNCLCC Grade 2 or 3 soft tissue sarcomas and will undergo surgical resection. Based upon the FDA label, successful protocols used for intraoperative fluorescence-guided visualization for glioma resections, and on drug company current dosing recommendation for this study, patients will be administered 20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgery. The use of 5-ALA fluorescence will be relevant for evaluating the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

NCT ID: NCT06252714 Not yet recruiting - Clinical trials for Pelvic Organ Prolapse

Impact of Defecation Posture on Ease of Bowel Movements in Patients With a Rectocele

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The study aims to determine if defecation posture, when using a defecation posture modification device (DPMD), will improve ease of bowel movements in patients with pelvic organ prolapse, specifically rectoceles.

NCT ID: NCT06252701 Recruiting - Obesity Clinical Trials

Diet and Depression

Start date: June 2024
Phase: N/A
Study type: Interventional

This study is a pilot open label crossover trial to assess the feasibility and acceptability of reducing ultra- processed foods (UPF) in a personalized manner from the diets of patients with major depressive disorder who eat a large percentage of UPF.